Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Rollover Safety Study
2024-515283-31-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 4, open-label trial of ruxolitinib in Neoplasm (4 arms), sponsored by Novartis. Primary endpoint: Frequency and severity of SAEs/AEs. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
Neoplasm
Beyond the preview
Go deeper on 2024-515283-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515283-31-00.